文献速递淋巴瘤

商业使用阿基仑赛与利索基仑赛治疗大B细胞淋巴瘤的真实世界比较

A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

本回顾性单中心分析比较了50例接受阿基仑赛(axi-cel)和37例接受利索基仑赛(liso-cel)的三线大B细胞淋巴瘤患者。两组完全缓解率无显著差异(72% vs 62%),中位随访11个月时12个月无进展生存率分别为59%和44%,但倾向性评分分析显示liso-cel组无进展生存劣于axi-cel组(HR 2.95,95%CI 1.14-7.60)。

要点

  • 阿基仑赛组完全缓解率72%,利索基仑赛组62%,差异无统计学意义。
  • 倾向性评分分析显示利索基仑赛组无进展生存劣于阿基仑赛组(HR 2.95,95%CI 1.14-7.60)。
  • 阿基仑赛组的细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和持续性中性粒细胞减少发生率均高于利索基仑赛组。

核心结论

  • 直接比较显示两组关键结局(缓解率和无进展生存)相似,但利索基仑赛较长的等待时间可能导致选择偏倚,倾向性评分校正后利索基仑赛组无进展生存劣于阿基仑赛组。
  • 作者认为这些发现需在多中心环境中进一步评估。

研究设计与样本

  • 回顾性分析,单中心,纳入2021年6月至2022年9月接受三线治疗的复发或难治性大B细胞淋巴瘤患者,阿基仑赛组50例,利索基仑赛组37例。

主要发现

  • 利索基仑赛组患者年龄较大,其余基线特征相似。
  • 从白细胞分离术到CAR-T细胞输注的中位时间利索基仑赛组为41天,显著长于阿基仑赛组的30天。
  • 完全缓解率阿基仑赛组为72%,利索基仑赛组为62%,差异无统计学意义。
  • 中位随访11个月,12个月无进展生存率阿基仑赛组为59%,利索基仑赛组为44%,差异无统计学意义。
  • 倾向性评分分析显示利索基仑赛组无进展生存劣于阿基仑赛组(HR 2.95,95%CI 1.14-7.60)。

局限性

  • 原文为单中心回顾性分析。
  • 利索基仑赛较长的等待时间可能导致选择偏倚,使更多有利特征的患者接受利索基仑赛。
  • 作者指出这些发现需在多中心环境中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are anti-CD19 chimeric antigen receptor (CAR) T-cell therapies approved for relapsed and refractory large B-cell lymphoma (LBCL); however, there is currently no published data on liso-cel outside of clinical trials nor any data comparing these therapies. In this retrospective analysis, we reviewed patients with LBCL receiving liso-cel or axi-cel at a single institution in the third-line setting. From June 2021 to September 2022, a total of 50 patients received axi-cel and 37 liso-cel. Baseline patient characteristics were similar, aside from older age in liso-cel recipients. The median time from leukapheresis to CAR T-cell infusion was significantly longer for liso-cel (41 days) than axi-cel (30 days). Complete response rates were not significantly different between axi-cel (72%) and liso-cel (62%). At a median follow-up of 11 months, progression-free survival (PFS) was not significantly different between axi-cel and liso-cel cohorts, with 12-month PFS of 59% and 44%, respectively. However, on a propensity score analysis, an inferior PFS was observed with liso-cel (hazard ratio, 2.95; 95% confidence interval , 1.14-7.60). The rates of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and prolonged neutropenia were higher with axi-cel than liso-cel. Overall, direct comparison of axi-cel and liso-cel cohorts shows similar key outcomes including response rate and PFS, but prolonged wait times for liso-cel may have resulted in biased selection of patients with more favorable characteristics for liso-cel. When accounting for these higher-risk characteristics, an inferior PFS is observed with liso-cel compared with axi-cel. These findings warrant further evaluation in a multicenter setting.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Looka A, Qualls DA, Matthews D, et al. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 2025. PMID: 39546746. doi:10.1182/bloodadvances.2024012992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。